| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
77,921,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
4,773,204 |
Avg
Vol: |
2,175,956 |
| 52
Week Range: |
$81.49 - $81.49 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P 400 MIDCAP |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-13 |
4 |
S |
$48.00 |
$316,800 |
D/D |
(6,600) |
20,062 |
|
- |
|
| Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-13 |
4 |
D |
$48.06 |
$40,274 |
D/D |
(838) |
26,662 |
|
- |
|
| Vaught Jeffry L |
Sr. Vice Pres., and Pres., R&D |
• – – |
2004-12-13 |
4 |
D |
$48.06 |
$36,670 |
D/D |
(763) |
20,138 |
|
- |
|
| Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-07 |
4 |
OE |
$27.63 |
$276,250 |
D/D |
10,000 |
27,500 |
|
- |
|
| Grebow Peter E |
Sr VP, Worldwide Technical Ops |
• – – |
2004-12-02 |
4 |
S |
$48.07 |
$1,379,395 |
D/D |
(28,600) |
38,921 |
|
- |
|
| Grebow Peter E |
Sr VP, Worldwide Technical Ops |
• – – |
2004-12-02 |
4 |
OE |
$7.88 |
$520,800 |
D/D |
31,600 |
67,521 |
|
- |
|
| Baldino Frank Jr |
Chairman & CEO |
• • – |
2004-11-08 |
4 |
S |
$49.50 |
$4,960,599 |
D/D |
(100,000) |
272,149 |
|
- |
|
| Baldino Frank Jr |
Chairman & CEO |
• • – |
2004-11-08 |
4 |
OE |
$8.25 |
$825,000 |
D/D |
100,000 |
372,149 |
|
- |
|
| Roche Robert P Jr |
Sr. V.P., Pharmaceutical Ops. |
• – – |
2004-03-23 |
4 |
S |
$55.58 |
$139,009 |
D/D |
(2,500) |
28,603 |
|
- |
|
| Egan William P |
Director |
– • – |
2004-03-19 |
4 |
S |
$56.09 |
$280,704 |
D/D |
(5,000) |
0 |
|
- |
|
| Witzel Horst |
Director |
– • – |
2004-03-16 |
4 |
S |
$55.06 |
$554,875 |
D/D |
(10,000) |
0 |
|
- |
|
| Witzel Horst |
Director |
– • – |
2004-03-16 |
4 |
OE |
$11.19 |
$111,870 |
D/D |
10,000 |
10,000 |
|
- |
|
| Baldino Frank Jr |
Chairman & CEO |
• • – |
2004-03-09 |
5 |
GD |
$0.00 |
$0 |
D/D |
85 |
389,016 |
|
- |
|
| Egan William P |
Director |
– • – |
2004-03-09 |
4 |
OE |
$13.00 |
$65,000 |
D/D |
5,000 |
5,000 |
|
- |
|
| Vaught Jeffry L |
Sr. VP, and Pres., R & D |
• – – |
2004-03-03 |
4 |
S |
$59.16 |
$475,961 |
D/D |
(8,046) |
20,901 |
|
- |
|
| Buchi J Kevin |
Sr. Vice President & CFO |
• – – |
2004-03-01 |
4 |
S |
$58.50 |
$945,462 |
D/D |
(16,161) |
55,891 |
|
- |
|
| Baldino Frank Jr |
Chairman & CEO |
• • – |
2004-02-24 |
4 |
S |
$57.31 |
$2,296,552 |
D/D |
(40,000) |
272,149 |
|
- |
|
| Greenacre Martyn D |
Director |
– • – |
2004-02-19 |
4 |
S |
$57.40 |
$287,237 |
D/D |
(5,000) |
0 |
|
- |
|
| Greenacre Martyn D |
Director |
– • – |
2004-02-19 |
4 |
OE |
$7.31 |
$36,565 |
D/D |
5,000 |
5,000 |
|
- |
|
| Buchi J Kevin |
Sr. Vice President & CFO |
• – – |
2003-12-19 |
4 |
OE |
$13.00 |
$48,750 |
D/D |
3,750 |
72,052 |
|
- |
|
| Roche Robert P Jr |
Sr. V.P., Pharmaceutical Ops. |
• – – |
2003-12-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
165 |
30,938 |
|
- |
|
| Roche Robert P Jr |
Sr. V.P., Pharmaceutical Ops. |
• – – |
2003-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
31,103 |
|
- |
|
| Vaught Jeffry L |
Sr. Vice Pres., and Pres., R&D |
• – – |
2003-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
28,947 |
|
- |
|
| Baldino Frank Jr |
Chairman & CEO |
• • – |
2003-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
312,149 |
|
- |
|
| Buchi J Kevin |
Sr. Vice President and CFO |
• – – |
2003-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
68,302 |
|
- |
|
491 Records found
|
|
Page 18 of 20 |
|
|
